Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Tuesday, May 21, 2024

Enveric, MindBio partner to advance psilocin prodrugs for mental health disorders

 You'll have to ask your competent? doctor the difference between psilocybin and psilocin because your doctor should already be familiar with all the benefits of psilocybin for stroke.

magic mushrooms (10 posts to October 2014)

psilocybin (14 posts to May 2014)

The latest here:

Enveric, MindBio partner to advance psilocin prodrugs for mental health disorders

Enveric Biosciences announced it has signed a nonbinding term sheet to out-license a class of novel psilocin prodrugs to MindBio Therapeutics, an agreement that could yield more than $66 million in sales.

“At Enveric, our drug-discovery engine has created more promising, patented therapeutics than we can commercialize alone, so finding a partner such as MindBio Therapeutics, that shares our passion to develop much-needed treatments for neuropsychiatric indications like depression, is a big win,” Joseph Tucker, PhD, Enveric Biosciences CEO, told Healio in an email.

The first patient with treatment-resistant depression was dosed with a psychedelic in a phase 2a study. Image: Adobe Stock
Enveric Biosciences has signed a nonbinding term sheet with MindBio Therapeutics, which will seek to advance a novel psilocin prodrug candidate for neuropsychiatric indications. Image: Adobe Stock

According to an Enveric press release, the company’s psilocin prodrug molecules are designed to release therapeutic levels of systemic psilocin at varying rates for treatment of anxiety, depression and substance abuse disorders. Other features include enhanced gastrointestinal stability, increased absorption properties and variable cleavable substitutions producing altered pharmacokinetic properties.

Terms of the signing permit MindBio to advance a drug candidate from Enveric’s novel psilocin prodrug class for neuropsychiatric indications. Upon entering into a definitive agreement, MindBio would receive an exclusive, global license to the formulations, drugs, method of use and devices developed to utilize the compound. MindBio would also assume responsibility for all future preclinical, clinical and commercial development on a royalty-bearing basis for all human and animal pharmaceutical applications, the also additionally revealed in the release.

Should a definitive agreement be reached, MindBio would pay Enveric development and sales milestones up to an aggregate $66.5 million as well as royalties ranging from 2.5% to 10% on all future sales.

“Enveric’s efforts are directed to maximize benefit to the patient and return to the shareholder by advancing as many of our drug candidates as possible, and these efforts are significantly facilitated when we find opportunities to do so in concert with equally committed partners,” Tucker told Healio.

No comments:

Post a Comment